Acute Urticaria
Conditions
Brief summary
This study is to investigate the pharmacokinetics (PK) together with the safety and tolerability of JDP-205 at 5 mg and 10 mg intravenous doses and 10 mg intramuscular dose, in comparison to the marketed cetirizine oral product Zyrtec® 10 mg tablets (an OTC product) in healthy male and female volunteers after a single dose administration.
Interventions
DRUGJDP-205 IV high dose
DRUGJDP-205 IV low dose
DRUGJDP-205 IM
DRUGControl: Zyrtec
Sponsors
Algorithme Pharma Inc
JDP Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Male or female volunteer 2. Volunteer aged of at least 18 years 3. Volunteer with a body mass index (BMI) greater than or equal to 18.50 and below 30.00 kg/m2 4. Non- or ex-smokers; an ex-smoker being defined as someone who completely stopped smoking for at least 12 months before day 1 of this study. 5. Availability for the entire study period 6. Motivated volunteer and absence of intellectual problems likely to limit the validity of consent to participate in the study or the compliance with protocol requirements; ability to cooperate adequately; ability to understand and observe the instructions of the physician or designee 7. Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without any clinical significance 8. Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on physical examination (including the examination of the anterolateral thigh muscles) and/or clinical laboratory evaluations (hematology, biochemistry, ECG and urinalysis) 9. Willingness to adhere to the protocol requirements as evidenced by the informed consent form (ICF) duly read, signed and dated by the volunteer
Exclusion criteria
1. Females who are pregnant or are lactating 2. Females of childbearing potential who refuse to use an acceptable contraceptive regimen throughout the entire duration of the study (from the screening visit until study completion) 3. History of significant hypersensitivity to cetirizine or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs 4. Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects 5. History of significant gastrointestinal, liver or kidney disease that may affect drug bioavailability 6. Presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease 7. Suicidal tendency, history of or disposition to seizures, state of confusion, clinically relevant psychiatric diseases 8. Presence of out-of-range cardiac interval (PR \< 110 msec, PR \> 200 msec, QRS \< 60 msec, QRS \>110 msec and QTc \> 440 msec) on the screening ECG or other clinically significant ECG abnormalities 9. Known presence of rare hereditary problems of galactose and /or lactose intolerance 10. Maintenance therapy with any drug, or significant history of drug dependency or alcohol abuse (\> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic) 11. Any clinically significant illness in the previous 28 days before day 1 of this study 12. Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and St John's Wort), in the previous 28 days before day 1 of this study 13. Use of antihistaminic medication in the previous 7 days before day 1 of this study 14. Any history of tuberculosis and/or prophylaxis for tuberculosis 15. Positive urine screening of ethanol and/or drugs of abuse 16. Positive results to HIV, HBsAg or anti-HCV tests 17. Females who are pregnant according to a positive serum pregnancy test 18. Volunteers who took an Investigational Product (in another clinical trial) or donated 50 mL or more of blood in the previous 28 days before day 1 of this study 19. Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before day 1 of this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in pharmacokinetics: Difference in AUC | 36 hours post dose |
| Differences in pharmacokinetics: difference in Cmax | 36 hours pose dose |
Countries
Canada
Outcome results
None listed